NCT00005818View on ClinicalTrials.gov

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

March 31, 2003

Conditions
Adenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
Interventions
DRUG

irinotecan hydrochloride

Given IV

DRUG

semaxanib

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005818 - SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter